Zai Lab
Christine Chiou currently serves as Senior Vice President of Investor Relations at Zai Lab since May 2023. Previously, Chiou led Investor Relations at Incyte from November 2019 to May 2023 and held the position of Director of Investor Relations at Allergan between May 2018 and October 2019. Chiou founded EZT Global, an international trading and consulting firm, where an e-commerce website was launched for a major retailer, and provided strategic consulting for Orbose LLC. As co-Founder and CMO of cTHRU Inc. from January 2015 to December 2016, Chiou developed a cloud-based platform connecting retailers and consumers, achieving semi-finalist status in the 2015 Miami Herald Business Plan Challenge. Earlier roles included Vice President of Equity Research at Barclays Capital, Analyst in the MBA Leadership Development Program at Daiichi Sankyo, and an internship at Diamondback Capital. Chiou holds an MBA in Finance from Columbia Business School and a BA in Chemistry from Bryn Mawr College.
This person is not in any teams
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.